Showing 1571-1580 of 5771 results for "".
- AcuFocus Announces First Commercial Patients Treated With the IC-8 Apthera IOLhttps://modernod.com/news/acufocus-announces-first-commercial-patients-treated-with-the-ic-8-apthera-iol/2481329/AcuFocus announced that Vance Thompson, MD, of Vance Thompson Vision, Sioux Falls, South Dakota has commercially implanted the first patients with the IC-8 Apthera IOL. The first and only small aperture, non-toric extended depth of focus IOL, the Apthera IOL is FDA approved fo
- Harrow Announces Availability of Fortisite Formulations for In-Office Usehttps://modernod.com/news/harrow-announces-availability-of-fortisite-formulations-for-in-office-use/2481322/Harrow announced the availability, for in-office use, of Fortisite (compounded Tobramycin 1.5% + Vancomycin 5%) from its FDA‑registered and FDA‑inspected ImprimisRx 503B outsourcing facility. Fortisite formulations are patent-pending high-concentration, refrigeration-stable, f
- Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directorshttps://modernod.com/news/iveric-bio-announces-the-addition-of-pravin-u-dugel-md-to-its-board-of-directors/2481317/Iveric bio announced the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023. Dr. Dugel has been instrumental in helping to shape the company’s business strategy and in overseeing the development and regulatory submission
- Bausch + Lomb and Glaucoma Research Foundation Announce Launch of "Screen, Protect, Cure" Campaignhttps://modernod.com/news/bausch-lomb-and-glaucoma-research-foundation-announce-launch-of-screen-protect-cure-campaign/2481316/Bausch + Lomb and Glaucoma Research Foundation (GRF) announced the US launch of "Screen, Protect, Cure," a campaign designed to provide educational resources and raise awareness of glaucoma during Glaucoma Awareness Month. “We are proud to collaborate with Glau
- Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCEDhttps://modernod.com/news/kala-pharmaceuticals-announces-fda-acceptance-of-ind-application-for-kpi-012-for-the-treatment-of-pced/2481312/Kala Pharmaceuticals announced that the FDA has accepted an investigational new drug (IND) application for the company’s lead product candidate, KPI-012, a human mesenchymal stem cell secretome (MSC-S), initially in development for the treatment of persistent corneal epithelial de
- Outlook Therapeutics Announces Validation of Marketing Authorization Application by the EMA for ONS-5010 for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-validation-of-marketing-authorization-application-by-the-european-medicines-agency-for-ons-5010-as-a-treatment-for-wet-amd/2481308/Outlook Therapeutics announced the validation of its marketing authorization application (MAA) by the European Medicines Agency (EMA) for ONS-5010 / Lytenava (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degener
- Elios Vision Announces Registration of Elios in Francehttps://modernod.com/news/elios-vision-announces-registration-of-elios-in-france/2481304/Elios Vision announced that its Elios technology, which is used to treat glaucoma at the same time as cataract surgery, is now registered in France. Elios does not require an implant and is designed to provide long-lasting results that may free patients from drop therapy.
- Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosishttps://modernod.com/news/ocugen-announces-ocu400-receives-orphan-drug-designations-for-retinitis-pigmentosa-and-leber-congenital-amaurosis/2481300/Ocugen announced that the FDA granted orphan drug designations to OCU400—human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3)—for the treatment of retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA). “Receiving orphan drug designation is
- GenSight Biologics Announces Publication of Indirect Comparison of Lumevoq Versus Natural History in ND4-LHON Patientshttps://modernod.com/news/gensight-biologics-announces-publication-of-indirect-comparison-of-lumevoq-versus-natural-history-in-nd4-lhon-patients/2481299/GenSight Biologics announced the publication of a peer-reviewed article in the journal Ophthalmology and Therapy highlighting updated efficacy results from a pooled analysis of four phase 3 studies showing an improvement in visual acuity in ND4-LHON patients treated with&n
- NovaSight Announces Commercial Release of CureSight in the US; Names a New VP of Sales & Marketinghttps://modernod.com/news/novasight-introduces-curesight-to-the-us-and-names-a-new-vp-of-sales-marketing/2481295/NovaSight has announced that its CureSight digital therapy for amblyopia will be released to the US market beginning this month. CureSight received FDA 510(K) clearance based on a pivotal study that found the device to be noninferior to eye patching—t